GlobeNewswire Inc.··Altimmune, Inc.Altimmune's Pemvidutide Shows Strong Metabolic Gains in MASH Trial Data
Altimmune's pemvidutide shows 23.7% triglyceride reduction and 7.5% weight loss in MASH Phase 2b trial, with Phase 3 planned mid-2026.
ALTPhase 3 trialweight loss